352 related articles for article (PubMed ID: 18297798)
1. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids.
Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S
Acta Biol Hung; 2007; 58 Suppl():113-29. PubMed ID: 18297798
[TBL] [Abstract][Full Text] [Related]
2. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.
Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S
Neurochem Int; 2008 Jan; 52(1-2):321-8. PubMed ID: 17698254
[TBL] [Abstract][Full Text] [Related]
3. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain.
Páldy E; Bereczki E; Sántha M; Wenger T; Borsodi A; Zimmer A; Benyhe S
Neurochem Int; 2008 Dec; 53(6-8):309-16. PubMed ID: 18804501
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice.
Berrendero F; Mendizábal V; Murtra P; Kieffer BL; Maldonado R
Eur J Neurosci; 2003 Oct; 18(8):2197-202. PubMed ID: 14622180
[TBL] [Abstract][Full Text] [Related]
5. Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain.
Pol O; Murtra P; Caracuel L; Valverde O; Puig MM; Maldonado R
Neuropharmacology; 2006 Jan; 50(1):123-32. PubMed ID: 16360182
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.
Zádor F; Otvös F; Benyhe S; Zimmer A; Páldy E
Neurochem Int; 2012 Aug; 61(3):378-88. PubMed ID: 22613132
[TBL] [Abstract][Full Text] [Related]
7. Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice.
Urigüen L; Berrendero F; Ledent C; Maldonado R; Manzanares J
Eur J Neurosci; 2005 Oct; 22(8):2106-10. PubMed ID: 16262648
[TBL] [Abstract][Full Text] [Related]
8. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
Zádor F; Kocsis D; Borsodi A; Benyhe S
Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors.
Canals M; Milligan G
J Biol Chem; 2008 Apr; 283(17):11424-34. PubMed ID: 18319252
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
11. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
12. The mu-opioid receptor down-regulates differently from the delta-opioid receptor: requirement of a high affinity receptor/G protein complex formation.
Chakrabarti S; Yang W; Law PY; Loh HH
Mol Pharmacol; 1997 Jul; 52(1):105-13. PubMed ID: 9224819
[TBL] [Abstract][Full Text] [Related]
13. The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.
Kracke GR; Stoneking SP; Ball JM; Tilghman BM; Washington CC; Hotaling KA; Johnson JO; Tobias JD
Naunyn Schmiedebergs Arch Pharmacol; 2007 Dec; 376(4):285-93. PubMed ID: 17960365
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system.
Zarrindast MR; Sarahroodi S; Arzi A; Khodayar MJ; Taheri-Shalmani S; Rezayof A
Behav Pharmacol; 2008 Oct; 19(7):716-23. PubMed ID: 18797248
[TBL] [Abstract][Full Text] [Related]
15. CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited.
Jardinaud F; Crété D; Canestrelli C; Ledent C; Roques BP; Noble F
Brain Res; 2005 Nov; 1063(1):77-83. PubMed ID: 16256959
[TBL] [Abstract][Full Text] [Related]
16. The delta-opioid receptor is sufficient, but not necessary, for spinal opioid-adrenergic analgesic synergy.
Chabot-Doré AJ; Millecamps M; Stone LS
J Pharmacol Exp Ther; 2013 Dec; 347(3):773-80. PubMed ID: 24039246
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.
Viganò D; Rubino T; Vaccani A; Bianchessi S; Marmorato P; Castiglioni C; Parolaro D
Psychopharmacology (Berl); 2005 Nov; 182(4):527-36. PubMed ID: 16079992
[TBL] [Abstract][Full Text] [Related]
18. Mu and delta opioid receptor immunoreactivity and mu receptor regulation in brainstem cells cultured from late fetal and early postnatal rats.
Kivell BM; Day DJ; McDonald FJ; Miller JH
Brain Res Dev Brain Res; 2004 Mar; 149(1):9-19. PubMed ID: 15013624
[TBL] [Abstract][Full Text] [Related]
19. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.
Chuchawankul S; Shima M; Buckley NE; Hartmann CB; McCoy KL
Int Immunopharmacol; 2004 Feb; 4(2):265-78. PubMed ID: 14996418
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids.
Börner C; Höllt V; Sebald W; Kraus J
J Leukoc Biol; 2007 Jan; 81(1):336-43. PubMed ID: 17041005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
